Bromantane

This article is a stub. As such, it may contain incomplete or wrong information. You can help by expanding it.

Bromantane
Chemical Nomenclature
Common names	Bromantane, Bromantan, Ladasten
Substitutive name	Bromantane
Systematic name	N-(4-Bromophenyl)adamantan-2-amine
Class Membership
Psychoactive class	Stimulant / Nootropic
Chemical class	Adamantane
Routes of Administration
WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section. ⇣ Oral Dosage Bioavailability 42% Threshold < 10 mg Light 10 - 50 mg Common 50 - 100 mg Strong 100 - 200 mg Heavy 200 mg + Duration Total 6 - 10 hours Onset 30 - 60 minutes Peak 2 - 4 hours DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.
Interactions

Summary sheet: Bromantane

Bromantane (trade name Ladasten / Ладастен) is a Russian pharmaceutical substance developed in the late 1980s that possesses both stimulant and anxiolytic properties. Although it is a commonly used medication in Russia and surrounding countries, it has not gained widespread recognition or pharmaceutical use in other countries. During the 1996 Olympic Games in Atlanta, 5 different Russian athletes tested positive for bromantane use.

A study conducted on human subjects displayed bromantane's ability to improve endurance and work capacity during stressful and intense conditions. This is because bromantane works as an actoprotector, a substance that makes the body more stable under physical duress without increasing oxygen consumption.

Chemistry

Adamantane molecule

Bromantane is a chemical derivative of adamantane, a polyhedral organic compound containing four fused cyclohexane rings. Bromantane's structure consists of adamantane bound at R₂ to a nitrogenous group which is in turn bonded to a phenyl ring substituted at R₄ with a bromine group.

Pharmacology

Bromantane is atypical among stimulants in the sense that it inhibits serotonin reuptake in addition to inhibiting dopamine reuptake. It also increases levels of norepinephrine, but its means of doing so are unclear. Bromantane's anxiolytic properties are due to its strengthening of GABA-ergic mediation.

Subjective effects

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects

• • Stimulation
  • Stamina enhancement
  • Dehydration
  • Vasoconstriction
  • Increased blood pressure
  • Muscle relaxation

Cognitive effects

• • Anxiety suppression
  • Focus enhancement
  • Thought acceleration
  • Analysis enhancement
  • Memory enhancement
  • Motivation enhancement
  • Cognitive euphoria
  • Wakefulness

Toxicity and harm potential

This toxicity and harm potential section is a stub. As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it. Note: Always conduct independent research and use harm reduction practices if using this substance.

Lethal dosage

The LD₅₀ of bromantane in mice has been established at 8100 mg/kg.

It is strongly recommended that one use harm reduction practices when using this substance.

Legal issues

This legality section is a stub. As such, it may contain incomplete or wrong information. You can help by expanding it.

• Russia - Bromantane is a prescription drug in Russia, its country of origin.
• United States - Bromantane is uncontrolled in the United States and has not been approved by the FDA for human use. However, this has led nootropic vendor websites to sell bromantane under the label of "not for human consumption."

See also

• Responsible use
• Tianeptine
• Noopept
• Nootropics

Literature

• Reichlin, S. (1969). Handbook of Experimental Pharmacology. The American Journal of The Medical Sciences (Vol. 258). https://doi.org/10.1097/00000441-196911000-00008
• Krapivin, S. V, Sergeeva, S. A., & Morozov, I. S. (1993). [A quantitative pharmaco-electroencephalographic analysis of the action of bromantane]. Biulleten’ Eksperimental’noi Biologii I Meditsiny, 116(11), 515–8. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/8312546
• Burnat, P., Payen, A., Brumant-Payen, C. Le, Hugon, M., & Ceppa, F. (1997). Bromontan, a new doping agent. The Lancet, 350(9082), 963–964. https://doi.org/10.1016/S0140-6736(05)63310-7
• Viatleva, O. A., Barchukov, V. G., Morozov, I. S., Salenko, I. A., & Zhirnov, E. N. (2000). [The neuro- and psychophysiological effects of bromantane]. Voenno-Meditsinskii Zhurnal, 321(8), 61–5, 96. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10998997
• Iezhitsa, I. N., Spasov, A. A., & Bugaeva, L. I. (2001). Effects of bromantan on offspring maturation and development of reflexes. Neurotoxicology and Teratology, 23(2), 213–222. https://doi.org/10.1016/S0892-0362(01)00119-2
• Iezhitsa, I. N., Spasov, A. A., Bugaeva, L. I., & Morozov, I. S. (2002). Toxic effect of single treatment with bromantane on neurological status of experimental animals. Bulletin of Experimental Biology and Medicine, 133(4), 380–383. https://doi.org/10.1023/A:1016206306875
• Oliynyk, S., & Oh, S. (2012). The pharmacology of actoprotectors: Practical application for improvement of mental and physical performance. Biomolecules and Therapeutics, 20(5), 446–456. https://doi.org/10.4062/biomolther.2012.20.5.446
• Morozov, I. S., Klimova, N. V, Karpova, T. D., & Shestopalov, S. S. (n.d.). [The characteristics of the neuropsychotropic activity of bromantane in laboratory animals]. Eksperimental’naia I Klinicheskaia Farmakologiia, 62(2), 3–6. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10340117
• Kudrin, V. S., Sergeeva, S. A., Krasnykh, L. M., Miroshnichenko, I. I., Grekhova, T. V, & Gaĭnetdinov, R. R. (n.d.). [The effect of bromantane on the dopamin- and serotoninergic systems of the rat brain]. Eksperimental’naia I Klinicheskaia Farmakologiia, 58(4), 8–11. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/7580761